Veterans, individuals with kidney disease being asked to test new app

Veterans and other individuals managing kidney disease are being asked to test a new nutrition-tracking mobile application designed to help kidney patients.

The American Association of Kidney Patients (AAKP) announced it’s partnering with the American Society of Nephrology (ASN) and U.S. Department of Veteran Affairs (VA) to encourage patients to test the new MyKidneyNutrition app before it launches.

The app—developed by the ASN and the VA—allows patients to track their daily activities like nutrition, fitness and medication information. The organizations hope the app will help patients lead healthier and “more kidney-friendly” lives.

“ASN is honored to be able to once again collaborate with AAKP through the testing of the MyKidneyNutrition app,” former ASN President Sharon Moe, MD, said in a press release. “We look forward to the feedback we receive from kidney patients that volunteer to test the app before its public release, thus ensuring that the MyKidneyNutrition app truly address the needs of kidney patients.”

The organizations plan to identify both veterans and non-veterans to test the app before it launches. People interested in testing the app should contact Erin Kahle, AAKP director of stakeholder operations, at ekahle@aakp.org.

“Participating in the testing of this mobile app is an important step in making a real difference in the future of kidney care for both veterans and other individuals impacted by kidney disease,” Edward Hickey III, AAKP Veterans Health Initiative chair, said. “Veterans are natural consumers of technology and the ability to use a new tool to manage their kidney health is a welcome innovation.”

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup